At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 25 enrolled
Drug / intervention
Ketaminedrug
Likely dose
Ketamine 0.5 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Precision Medicine With Ketamine for Older Adults With Treatment-resistant Depression: Pilot Study
In Brief
A Phase 4 clinical trial evaluating Ketamine for Treatment Resistant Depression and 4 related conditions. Completed, enrolled 25 participants across 5 sites in 2 countries.
Detailed Summary
This pilot study will assess the safety and feasibility of intravenous (IV) ketamine in older adults with Treatment-Resistant Depression (TRD). In addition, this study will develop and utilize innovative methodological approaches to demonstrate the feasibility of precision medicine and mobile health approaches in depression treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTreatment Resistant Depression, Refractory Depression, Therapy-Resistant Depression, Late Life Depression, Geriatric Depression
CountriesCanada, United States
Collaborators--
Timeline
Phase 4CompletedFinished
202120222023202420252026
First PostedAug 2020
Enrollment StartOct 2020
Primary CompletionNov 2021
Study CompletionMar 2022
TodayJul 2026
First PostedAug 7, 2020
Enrollment StartOct 22, 2020
Primary CompletionNov 30, 2021
Study CompletionMar 15, 2022
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 5.9 years ago
Interventions
Ketaminedrug
ketamine will be infused using an IV infusion pump at a rate of 0.5 mg/kg of body weight over 40 minutes